VANCOUVER, BC / ACCESSWIRE / February 6, 2020 / Hemagenetics Technologies Corp. (the “Company” or “HTC”) announces that Ronald Ozols has resigned effective immediately as director and CFO and Mr. Patrick Brown has been appointed as his replacement.
Bio for new director and CFO:
Mr. Brown, 53, is an experienced and formally trained Chartered Accountant with over 25 years in senior audit and finance roles. Mr. Brown currently operates Parabolic Communications Inc. that provides marketing and investor relations services with professional experience in public markets and investor relations, having managed programs for several OTC registered entities.
For further information please contact:
J. Scott Munro, CEO and Director
Hemagenetics Technologies Corp.
Cautionary Note Regarding Forward Looking Information
This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company such as the statement that: (i) the Arrangement may be effected or final court order for the same obtained; and (ii) shareholders may receive 100% of the shares of each of the other parties to the Arrangement under the Arrangement Agreement. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) the inability to complete the Arrangement; and (ii) other factors beyond the Company’s control. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.
SOURCE: Hemagenetics Technologies Corp.
View source version on accesswire.com: